Nicotinamide ribose phosphate transferase mutant and application thereof

By mutation of specific sites of nicotinamide phosphate ribose transferase, a highly active mutant was constructed and whole-cell catalysis was used to use recombinant Saccharomyces cerevisiae, the problem of insufficient NMN yield in the prior art was solved, and a significant increase in NMN yield was achieved.

CN118931864APending Publication Date: 2024-11-12SERAGON BIOSCIENCES INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410065678.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-01-16
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The catalytic activity of existing nicotinamide phosphate ribose transferases is low, which limits the improvement of nicotinamide single nucleotide (NMN) production, and the existing mutation scheme has limited effect and cannot significantly increase the production of NMN.

Method used

By performing single-point mutations on valine at 75 and aspartic acid at 83 of nicotinamide phosphate ribose transferase, a mutant with higher activity was designed, and the corresponding recombinant Saccharomyces cerevisiae was constructed, and the whole cell was used to perform Catalytic synthesis of NMN.

Benefits of technology

The production of NMN was significantly improved, and the production of NMN of the mutant was 4.3 times to 5.3 times higher than that of the wild type, providing a theoretical basis for industrialized production of NMN.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931864A_ABST
    Figure CN118931864A_ABST
Patent Text Reader

Abstract

The invention discloses a nicotinamide ribose phosphate transferase mutant and application thereof. According to the invention, a wild type of nicotinamide phosphoribosyltransferase is taken as a parent, and the 75th amino acid or 83rd amino acid is subjected to point mutation, so that the mutant with activity obviously improved compared with that of the wild type and the recombinant saccharomyces cerevisiae for expressing the mutant are obtained. Compared with a wild type, the mutant disclosed by the invention can be used for remarkably improving the yield of the NMN. Wherein the yield of the NMN of the mutant obtained by mutating the 75th amino acid is increased by 4.3 times as high as that of the wild type, and the yield of the NMN of the mutant obtained by mutating the 83rd amino acid is increased by 5.3 times as high as that of the wild type. According to the method, a theoretical basis is provided for further improving the yield of the NMN, large-scale production of the NMN is facilitated, and development of the NMN industry is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of genetic engineering technology and more specifically relates to a nicotinamide phosphoribosyltransferase mutant and its application. Background Art

[0002] Nicotinamide Mononucleotide (NMN) is a natural biologically active nucleotide belonging to V B The derivatives of this family have high food safety and can be used to improve aging and metabolic diseases. However, the current production of NMN cannot meet its growing demand, and a method to increase the production of NMN is urgently needed.

[0003] At present, there are two main methods for the synthesis of NMN: chemical synthesis and biosynthesis. Chemical synthesis has problems such as high energy consumption, harsh reaction conditions, and serious environmental pollution in the production process. Therefore, the biosynthesis method of NMN is more popular. The existing biosynthesis methods of NMN mainly use glucose and nicotinamide as substrates, use nicotinamide phosphoribosyltransferase for catalytic synthesis, or use recombinant bacteria expressing nicotinamide phosphoribosyltransferase for whole-cell catalysis; the former method of directly using enzymes for catalysis is not as advantageous as the latter method of using recombinant bacteria for whole-cell catalysis due to problems such as easy enzyme inactivation.

[0004] Nicotinamide phosphoribosyltransferase (Nampt) is a key enzyme in the biosynthesis of NMN, but the activity of the natural enzyme is not high, which limits the large-scale production of NMN. In order to increase the production of NMN, technicians have tried to increase the catalytic activity of the enzyme by mutating nicotinamide phosphoribosyltransferase, thereby increasing the production of NMN per unit time. In the currently disclosed mutation schemes, for the core region of nicotinamide phosphoribosyltransferase, there are more mutations in the 100-450 interval sites (the most mutations are for the 200-400 interval sites). However, research data show that the effects of mutants obtained by mutation at different sites are significantly different. The degree of improvement in the catalytic activity of most mutants currently disclosed is limited, and its catalytic activity is less than 1 times that of the wild type, and it cannot significantly increase the production of NMN. Therefore, it is of great significance to the NMN industry to continue to explore mutation sites and mutation methods. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides a nicotinamide phosphoribosyltransferase mutant and application thereof.

[0006] The first object of the present invention is to provide a method for increasing the activity of nicotinamide phosphoribosyltransferase.

[0007] The second object of the present invention is to provide a nicotinamide phosphoribosyltransferase mutant.

[0008] The third object of the present invention is to provide a gene encoding the mutant.

[0009] The fourth object of the present invention is to provide a recombinant plasmid.

[0010] The fifth object of the present invention is to provide a recombinant bacterium.

[0011] The sixth object of the present invention is to provide the use of the mutant, the gene, the recombinant plasmid or the recombinant bacteria in the biosynthesis of nicotinamide mononucleotide.

[0012] The seventh object of the present invention is to provide the use of the mutant, the gene, the recombinant plasmid or the recombinant bacteria in the preparation of a product for the biosynthesis of nicotinamide mononucleotide.

[0013] The eighth object of the present invention is to provide a method for high-yield nicotinamide mononucleotide.

[0014] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0015] The invention uses the wild type of nicotinamide phosphoribosyltransferase (Nampt) as a parent, performs semi-rational design of the enzyme, and obtains mutation sites and corresponding mutants capable of improving the catalytic activity of nicotinamide phosphoribosyltransferase.

[0016] The present invention claims a method for improving the activity of nicotinamide phosphoribosyltransferase, the method comprising: mutating the 75th valine of nicotinamide phosphoribosyltransferase to any amino acid except lysine;

[0017] Or the 83rd aspartic acid of nicotinamide phosphoribosyltransferase is mutated to leucine, lysine, cysteine, proline, isoleucine, histidine, methionine, glycine, tyrosine, valine, glutamic acid or asparagine.

[0018] Specifically, the reference sequence (NCBI Reference Sequence) of the nicotinamide phosphoribosyltransferase of the present invention in NCBI is WP_012788281.1.

[0019] Specifically, the mutating of the valine at position 75 of nicotinamide phosphoribosyltransferase into any amino acid except lysine refers to mutating it into any other natural amino acid except lysine.

[0020] The present invention also seeks to protect a nicotinamide phosphoribosyltransferase mutant, which is obtained by performing point mutation on a specific amino acid site of the reference sequence WP_012788281.1 using the above method.

[0021] As one embodiment, the mutant is constructed by designing corresponding site-directed mutagenesis primers and amplifying the mutant by reverse PCR. The gene sequence encoding the wild-type nicotinamide phosphoribosyltransferase is shown in SEQ ID NO.1.

[0022] The present invention also claims a gene encoding the mutant.

[0023] Although the present invention does not provide the amino acid or gene sequence of each mutant, based on the known amino acid sequence of the parent, the amino acid sequence of the corresponding mutant can be obtained by knowing the amino acid after the mutation site is mutated, and then the corresponding gene sequence can be obtained. In addition to mutating the parent, the corresponding mutant can also be obtained by artificial synthesis and other methods based on the sequence of the mutant. Therefore, the present invention also requests protection for the gene encoding the mutant. Using the gene, the corresponding mutant can be obtained by recombinant expression.

[0024] The present invention also claims protection for a recombinant plasmid, which is used to express the mutant of the present invention.

[0025] Specifically, the recombinant plasmid contains a gene encoding the mutant of the present invention.

[0026] Optionally, the vector used to construct the plasmid is pRS306.

[0027] The present invention also claims protection for a recombinant bacterium, which is capable of expressing the mutant of the present invention.

[0028] As one embodiment, the recombinant bacteria contains a recombinant plasmid for expressing the mutant of the present invention.

[0029] Optionally, when constructing recombinant bacteria, Escherichia coli or Saccharomyces cerevisiae can be selected as the starting strain.

[0030] The present invention also claims protection for the use of the mutant, the gene, the recombinant plasmid or the recombinant bacteria in the biosynthesis of nicotinamide mononucleotide.

[0031] The present invention also claims protection for the use of the mutant, the gene, the recombinant plasmid or the recombinant bacteria in preparing a product for biosynthesis of nicotinamide mononucleotide.

[0032] The present invention also provides a method for high production of nicotinamide mononucleotide, the method comprising: replacing the nicotinamide phosphoribosyltransferase used in producing nicotinamide mononucleotide with the nicotinamide phosphoribosyltransferase mutant of the present invention, or replacing the recombinant bacteria expressing nicotinamide phosphoribosyltransferase used in producing nicotinamide mononucleotide with the recombinant bacteria of the present invention.

[0033] As a specific embodiment, the method is: using glucose and nicotinamide as substrates, and utilizing the recombinant bacteria of the present invention to perform whole-cell catalysis.

[0034] Specifically, in the method, the concentration of the substrate glucose is 50-90 g / L, and the concentration of the substrate nicotinamide is 10-20 g / L.

[0035] Preferably, in the method, the concentration of the substrate glucose is 60-80 g / L, and the concentration of the substrate nicotinamide is 10-15 g / L.

[0036] More preferably, in the method, the concentration of the substrate glucose is 70 g / L, and the concentration of the substrate nicotinamide is 10 to 15 g / L. Under this substrate concentration condition, the yield of NMN prepared by whole-cell catalysis using the recombinant bacteria is relatively the highest.

[0037] Specifically, in the method, the OD of the recombinant bacteria is 600 It is 28 to 32.

[0038] More specifically, in the method, the OD of the recombinant bacteria is 600 is 30.

[0039] Specifically, the recombinant bacteria is a recombinant Saccharomyces cerevisiae capable of expressing the mutant of the present invention.

[0040] The present invention has the following beneficial effects:

[0041] The present invention discloses a nicotinamide phosphoribosyltransferase mutant and its application. The mutation scheme of the present invention is: a single-point mutation is performed on the 75th amino acid or the 83rd amino acid in the 1st to 100th interval of the wild type of nicotinamide phosphoribosyltransferase to obtain a mutant with significantly improved activity compared with the wild type. Based on the mutation scheme, the present invention also constructs a recombinant brewer's yeast capable of expressing the mutant. Compared with the wild type, the mutant of the present invention can significantly increase the NMN production. Among them, the NMN production of the mutant obtained by mutating the amino acid at the 75th amino acid is up to 4.3 times higher than that of the wild type, and the NMN production of the mutant obtained by mutating the amino acid at the 83rd amino acid is up to 5.3 times higher than that of the wild type. The present invention provides a theoretical basis for further improving the NMN production, which is conducive to the large-scale production of NMN and promotes the development of the NMN industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Figure 1 is the result of colony PCR detection after the recombinant expression plasmid pRS306-Cp-Nampt was transferred into Saccharomyces cerevisiae CEN.PK2-1C; Figure A is the result of colony PCR detection; Figure B is the plasmid map of the recombinant expression plasmid pRS306-Cp-Nampt.

[0043] Figure 2 Figure 1 is the colony PCR detection result after the recombinant expression plasmids with site-directed mutation and double mutation were transferred into Saccharomyces cerevisiae CEN.PK2-1C; Figure A is the colony PCR detection result after the recombinant expression plasmids with site-directed mutation were transferred into Saccharomyces cerevisiae CEN.PK2-1C, in which 1 corresponds to V75F, 2 corresponds to D83N, 3 corresponds to M139D, and 4 corresponds to L240W; Figure B is the colony PCR detection result after the recombinant expression plasmids with double mutation (V75F-D83N) were transferred into Saccharomyces cerevisiae CEN.PK2-1C.

[0044] Figure 3 Results of NMN production assay of recombinant Saccharomyces cerevisiae expressing wild-type nicotinamide phosphoribosyltransferase and V75F, D83N, M139D, L240W and V75F-D83N mutants.

[0045] Figure 4 The results of NMN production determination of recombinant Saccharomyces cerevisiae expressing 19 mutants of amino acid 75 of nicotinamide phosphoribosyltransferase.

[0046] Figure 5 The results of NMN production determination of recombinant Saccharomyces cerevisiae expressing 19 mutants of amino acid 83 of nicotinamide phosphoribosyltransferase.

[0047] Figure 6 Figure 1 shows the results of NMN production of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant D83N or V75F under different substrate concentrations; Figure A shows the results of NMN production of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant D83N under different glucose concentrations; Figure B shows the results of NMN production of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant D83N under different nicotinamide concentrations; Figure C shows the results of NMN production of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant V75F under different glucose concentrations; Figure D shows the results of NMN production of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant V75F under different nicotinamide concentrations. DETAILED DESCRIPTION

[0048] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0049] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0050] Example 1 Construction of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase and its mutants

[0051] The present invention uses the wild type of nicotinamide phosphoribosyltransferase (WT) as a parent, performs semi-rational design of the enzyme, and obtains mutation sites that may affect the catalytic activity of nicotinamide phosphoribosyltransferase. The reference sequence (NCBI Reference Sequence) of the wild type of nicotinamide phosphoribosyltransferase in NCBI is WP_012788281.1.

[0052] On this basis, the present invention mutates the 75th valine (V) of the wild-type nicotinamide phosphoribosyltransferase to phenylalanine (F), the 83rd aspartic acid (D) to asparagine (N), the 139th methionine (M) to aspartic acid (D), the 240th leucine (L) to tryptophan (W), the 75th valine (V) to phenylalanine (F), and the 83rd aspartic acid (D) to asparagine (N).

[0053] In order to facilitate the construction and acquisition of a mutant of nicotinamide phosphoribosyltransferase, the present invention performs codon optimization on the coding gene of nicotinamide phosphoribosyltransferase, and constructs a recombinant cerevisiae expressing the wild-type nicotinamide phosphoribosyltransferase using the optimized gene sequence (shown in SEQ ID NO.1), and on this basis, constructs a recombinant cerevisiae expressing the above-mentioned nicotinamide phosphoribosyltransferase mutant.

[0054] The construction process of the recombinant Saccharomyces cerevisiae of the present invention is as follows:

[0055] 1. Entrust GENEWIZ (Suzhou GENEWIZ Biotechnology Co., Ltd.) to synthesize the optimized gene sequence (shown in SEQ ID NO.1) and connect it to the vector pRS306 to obtain the recombinant expression plasmid 1 (pRS306-Cp-Nampt) and the recombinant bacteria 1 (recombinant Escherichia coli expressing wild-type nicotinamide phosphoribosyltransferase);

[0056] 2. Introducing site-directed mutations and double mutations by inverse PCR; using the recombinant expression plasmid 1 as a template, using site-directed mutation primers and high-fidelity enzymes designed for the mutations, performing inverse PCR amplification and performing electrophoresis detection;

[0057] 3. Recover the PCR amplification product using a gel recovery kit, digest the recovered PCR amplification product with DpnⅠ enzyme, transform E. coli competent cells after digestion, select positive clones for colony PCR detection and sequencing, retain the positive clones verified by sequencing, and obtain recombinant bacteria 2, that is, recombinant E. coli expressing nicotinamide phosphoribosyltransferase mutant; wherein the primers used for colony PCR are yz-1 and yz-2, and their nucleotide sequences are as follows:

[0058] yz-1:GCAATTAACCCTCACTAAAGGGAAC

[0059] yz-2:CAAGGCGATTAAGTTGGGTAACG

[0060] 4. Amplify the positive clones that have been detected correctly and extract the recombinant expression plasmid contained therein to obtain recombinant expression plasmid 2. Use StuⅠ enzyme to linearize the recombinant expression plasmid 2 and transform it into Saccharomyces cerevisiae (CEN.PK2-1C). Select the positive clones for colony PCR detection and sequencing to obtain recombinant bacteria 3, that is, recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant.

[0061] The constructed recombinant expression plasmid 1 is subjected to step 4 to obtain a recombinant Saccharomyces cerevisiae expressing the wild-type nicotinamide phosphoribosyltransferase (recombinant strain 4).

[0062] Specifically, the amino acid and base changes of the nicotinamide phosphoribosyltransferase mutant of the present invention are shown in Table 1; the site-directed mutagenesis primers designed for the mutation are shown in Table 2.

[0063] Table 1 Amino acid and base changes of nicotinamide phosphoribosyltransferase mutants

[0064]

[0065] Table 2 Site-directed mutagenesis primers

[0066]

[0067]

[0068] The reaction system used for inverse PCR amplification was: 1 μL of primers F / R, DNA template <1 ng, 25 μL of phanta high-fidelity enzyme, and 50 μL of ddH2O. The reaction program used for inverse PCR amplification was: 95℃ pre-denaturation for 3 min; 95℃ denaturation for 30 s, 55℃ annealing for 30 s, 72℃ extension for 5 min, 34 cycles; 72℃ extension for 5 min. The reaction system used for colony PCR was: 1 μL of primers yz1 / yz2, 1 μL of yeast genomic DNA, 10 μL of Premix Taq enzyme, and 20 μL of ddH2O. The reaction program used for colony PCR was: 95℃ pre-denaturation for 10 min; 95℃ denaturation for 30 s, 55℃ annealing for 30 s, 72℃ extension for 2 min, 29 cycles; 72℃ extension for 5 min.

[0069] Specifically, the process of transforming E. coli competent cells is:

[0070] (1) Add 10 μL of the product to be transformed into one tube of competent cells and place on ice for 30 min;

[0071] (2) Heat shock in a 42°C water bath for 90 seconds and in an ice bath for 2 minutes;

[0072] (3) Add 800 μL of 37°C LB medium (liquid) to each tube and incubate at 37°C on a shaker at 220 rpm for 1 h;

[0073] (4) Centrifuge at 8000 rpm for 1 min, discard the supernatant, resuspend the cells and spread them on a Kan-resistant LB plate, and culture in a 37°C incubator until a single colony grows.

[0074] The process of transforming Saccharomyces cerevisiae is:

[0075] (1) Pick a single colony of Saccharomyces cerevisiae and culture it overnight in 2 mL YPD. Transfer it to 48 mL YPD and culture it until OD 600 =1.3~1.5;

[0076] (2) Take 3 1.5 mL EP tubes, take 1 mL of bacterial solution in each tube, and centrifuge at 13000 rpm at 4°C for 5 min;

[0077] (3) Discard the supernatant, resuspend and wash with 1 mL of pre-cooled sterile water, and centrifuge at 13,000 rpm at 4°C for 5 min;

[0078] (4) Resuspend and wash with 200 μL of pre-cooled sterile water, combine three tubes into one, and centrifuge at 13,000 rpm at 4°C for 5 min;

[0079] (5) Resuspend and wash with 200 μL of pre-cooled 0.1 M LiAc, and centrifuge at 13,000 rpm at 4°C for 1 min;

[0080] (6) Resuspend in 100 μL of pre-cooled 0.1 M LiAc to obtain Saccharomyces cerevisiae competent cells and store on ice;

[0081] (7) Boil water, boil salmon essence for 5 minutes, and cool for 5 minutes;

[0082] (8) Centrifuge the competent cells at 13,000 rpm at 4°C for 1 min and discard the supernatant;

[0083] (9) Add 36 μL 1 M LiAc to resuspend, 240 μL PEG, 10 μL salmon sperm, and 2000 ng DNA to be transformed, and shake for 10 s;

[0084] (10) 30°C metal bath for 30 min, 42°C metal bath for 25 min, centrifugation at 13,000 rpm for 1 min;

[0085] (11) Discard the supernatant, add 600 μL of sterile water, resuspend, spread on SD-Ura plates, and culture in a 30°C incubator until a single colony grows.

[0086] The results of colony PCR detection after the recombinant expression plasmid pRS306-Cp-Nampt was transferred into Saccharomyces cerevisiae CEN.PK2-1C are as follows Figure 1 As shown; Figure 1 A in the figure is the result of colony PCR test; Figure 1 B in Figure 1 is the plasmid map of the recombinant expression plasmid pRS306-Cp-Nampt. Figure 1 It can be seen that the present invention successfully constructed a recombinant Saccharomyces cerevisiae expressing the wild-type nicotinamide phosphoribosyltransferase.

[0087] The results of colony PCR detection after the site-directed mutagenesis and double-mutation recombinant expression plasmids were transferred into Saccharomyces cerevisiae CEN.PK2-1C are as follows: Figure 2 As shown; Figure 2 A in the figure is the result of colony PCR detection after the site-directed mutagenesis recombinant expression plasmid was transferred into Saccharomyces cerevisiae CEN.PK2-1C. In the figure, the mutation corresponding to 1 is V75F, the mutation corresponding to 2 is D83N, the mutation corresponding to 3 is M139D, and the mutation corresponding to 4 is L240W; Figure 2 B in the figure is the colony PCR test result after the recombinant expression plasmid with double mutation (V75F-D83N) was transferred into Saccharomyces cerevisiae CEN.PK2-1C. Figure 2 It can be seen that the present invention successfully constructed recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase V75F, D83N, M139D, L240W and V75F-D83N mutants.

[0088] Example 2 Catalytic synthesis of nicotinamide mononucleotide by whole cells of recombinant Saccharomyces cerevisiae

[0089] The correctly sequenced recombinant Saccharomyces cerevisiae expressing the wild type and V75F, D83N, M139D, L240W and V75F-D83N mutants of nicotinamide phosphoribosyltransferase were inoculated into 10 mL of YPD liquid culture medium, respectively, and cultured at 30°C and 220 rpm for 15 h; then 4% of the culture solution was transferred to 50 mL of fermentation medium and cultured for 60 h; then centrifuged at 4°C and 8000 rpm for 5 min to collect the bacteria.

[0090] Yeast fermentation medium: contains 70 g / L glucose, 20 g / L peptone, 10 g / L yeast extract, 4 g / L KH2PO4, 2 g / L K2HPO4, 0.5 g / L MgSO4·7H2O, and 0.5 g / L NaCl.

[0091] The collected bacteria were used to synthesize nicotinamide mononucleotide by whole-cell catalysis. The reaction system used was: Glucose 70 g / L, Nam (nicotinamide) 15 g / L, and the bacterial OD 600 is 30; the reaction conditions used are: 220rpm, 30℃; samples were taken after 3h, 6h and 9h of reaction, and glass beads were added to the samples and then crushed with a high-pressure homogenizer for 60s, 30s interval, frequency 70, number 10, and the production of NMN was detected; the recombinant Saccharomyces cerevisiae transformed with pRS306-Cp-Nampt, that is, the recombinant Saccharomyces cerevisiae expressing the wild-type nicotinamide phosphoribosyltransferase was used as a control.

[0092] The detection of NMN production is carried out by chemical method, namely, the product NMN derivative reaction method. The specific process is as follows: take 69 μL of broken sample into a centrifuge tube, add 27.7 μL of 2mol / L KOH into the centrifuge tube, then add 27.7 μL of 20% acetophenone, vortex briefly to mix, and place in ice for 2 minutes; add 125 μL of 88% formic acid, centrifuge briefly at low speed, and react in a constant temperature oscillator at 37°C for 10 minutes; measure fluorescence: draw 240 μL of liquid from the centrifuge tube into the measurement well of a black 96-well plate, and use a Tecan multi-function microplate reader to measure fluorescence under excitation light of 382 nm and emission light of 445 nm; substitute the measured fluorescence value into the standard curve to obtain the concentration of NMN.

[0093] The results of NMN production assay of recombinant Saccharomyces cerevisiae expressing wild-type nicotinamide phosphoribosyltransferase and V75F, D83N, M139D, L240W and V75F-D83N mutants are shown in Figure 3 As shown. Figure 3It can be seen that when the whole cell catalytic reaction was 3h, the NMN production of the recombinant Saccharomyces cerevisiae expressing the single mutation D83N was 553.4mg / L. After 6h of reaction, the NMN production of the recombinant Saccharomyces cerevisiae expressing the single mutation V75F was 463.2mg / L, and the NMN production of the recombinant Saccharomyces cerevisiae expressing the wild-type Nampt was 88mg / L. By comparison, it can be seen that the single mutation D83N significantly increased the activity of the wild-type Nampt, and its NMN production increased by 5.3 times compared with the wild type. The single mutation V75F also significantly increased the activity of the wild-type Nampt, making its NMN production 4.3 times higher than the wild type under the same conditions.

[0094] Example 3 Saturation Mutation of Nicotinamide Phosphoribosyltransferase V75 and D83 Sites

[0095] In order to study the effects of other mutations of amino acids 75 and 83 of nicotinamide phosphoribosyltransferase on enzyme activity, the present invention uses the amino acid sequence of the wild type of nicotinamide phosphoribosyltransferase as a parent, and performs saturation mutations on amino acids 75 and 83, respectively. The construction method of the mutant corresponding to the saturation mutation is the same as that in Example 1, and corresponding mutation primers are designed for the desired mutation, and the mutated sequence is obtained by inverse PCR amplification.

[0096] Referring to the method described in Example 1, the present invention successfully constructed recombinant Saccharomyces cerevisiae with 18 other mutations of amino acid 75 and amino acid 83 of nicotinamide phosphoribosyltransferase. Based on the obtained recombinant Saccharomyces cerevisiae, the whole-cell catalysis was carried out using the method described in Example 2 and the NMN production was measured.

[0097] The results of NMN production assay of recombinant Saccharomyces cerevisiae expressing 19 mutants of nicotinamide phosphoribosyltransferase at amino acid position 75 are shown in Figure 4 As shown. Figure 4 It can be seen that except for the slight decrease in NMN production compared to the wild type after the 75th valine was mutated to lysine, the NMN production of the other mutations was higher than that of the wild type.

[0098] The results of NMN production assay of recombinant Saccharomyces cerevisiae expressing 19 mutants of nicotinamide phosphoribosyltransferase at amino acid position 83 are shown in Figure 5 As shown. Figure 5 It can be seen that mutating the 83rd aspartic acid to leucine (L), lysine (K), cysteine ​​(C), proline (P), isoleucine (I), histidine (H), methionine (M), glycine (G), tyrosine (Y), valine (V), glutamic acid (E) or asparagine (N) can increase its NMN production.

[0099] Example 4 Optimization of substrate concentration in whole cell catalytic reaction system

[0100] Based on the whole-cell catalytic reaction system described in Example 2, the present invention uses recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant D83N or V75F as the test strain to optimize the concentrations of substrate glucose and nicotinamide. A single-factor experiment was conducted, with the glucose concentration selected at 50 / 70 / 90 g / L and the nicotinamide concentration selected at 10 / 15 / 20 g / L. The bacterial OD 600 The concentration of NMN in the mixture was 30, and whole-cell catalysis was carried out according to the method described in Example 2. The NMN production was measured after 3 hours of reaction.

[0101] The results of NMN production in recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutants D83N or V75F under different substrate concentrations are shown in Figure 2. Figure 6 As shown; Figure 6 A in the figure is the NMN production measurement result under different glucose concentration conditions; Figure 6 B in the figure is the NMN production measurement result under different nicotinamide concentration conditions; Figure 6 C in the figure is the NMN production measurement result of the recombinant Saccharomyces cerevisiae expressing the nicotinamide phosphoribosyltransferase mutant V75F under different glucose concentration conditions; Figure 6 D in the figure is the NMN production measurement result of recombinant Saccharomyces cerevisiae expressing nicotinamide phosphoribosyltransferase mutant V75F under different nicotinamide concentration conditions. Figure 6 It can be seen that for the recombinant Saccharomyces cerevisiae expressing the nicotinamide phosphoribosyltransferase mutant D83N, the optimal concentration of glucose is 70g / L, at which time the NMN production is 524.8mg / L; the optimal concentration of nicotinamide is 15g / L, at which time the NMN production is 529.8mg / L. For the recombinant Saccharomyces cerevisiae expressing the nicotinamide phosphoribosyltransferase mutant V75F, the optimal concentration of glucose is 70g / L, at which time the NMN production is 442.3mg / L; the optimal concentration of nicotinamide is 10g / L, at which time the NMN production is 427.7mg / L.

[0102] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for increasing the activity of nicotinamide phosphoribosyltransferase, It is characterized in that Mutating the valine at position 75 of nicotinamide phosphoribosyltransferase to any amino acid except lysine; Or the aspartic acid at position 83 of nicotinamide phosphoribosyltransferase is mutated to leucine, lysine, cysteine, proline, isoleucine, histidine, methionine, glycine, tyrosine, valine, glutamic acid or asparagine.

2. A nicotinamide phosphoribosyltransferase mutant, It is characterized in that The mutant is obtained by the method of claim 1.

3. A gene encoding the mutant according to claim 2.

4. A recombinant plasmid, It is characterized in that Contains the gene according to claim 3.

5. A recombinant bacterium, It is characterized in that Express the mutant according to claim 2.

6. Use of the mutant according to claim 2, the gene according to claim 3, the recombinant plasmid according to claim 4 or the recombinant bacteria according to claim 5 in the biosynthesis of nicotinamide mononucleotide.

7. Use of the mutant according to claim 2, the gene according to claim 3, the recombinant plasmid according to claim 4 or the recombinant bacterium according to claim 5 in the preparation of a product for biosynthesis of nicotinamide mononucleotide.

8. A method for high yield of nicotinamide mononucleotide, It is characterized in that The nicotinamide phosphoribosyltransferase used in producing nicotinamide mononucleotide is replaced with the nicotinamide phosphoribosyltransferase mutant according to claim 2, or the recombinant bacteria expressing nicotinamide phosphoribosyltransferase used in producing nicotinamide mononucleotide is replaced with the recombinant bacteria according to claim 5.

9. The method according to claim 8, It is characterized in that In the method, the concentration of the substrate glucose is 50-90 g / L, and the concentration of the substrate nicotinamide is 10-20 g / L.

10. The method according to claim 9, It is characterized in that In the method, the OD of the recombinant bacteria 600 It is 28 to 32.